Skip to content

Thursday, April 23, 2026

Latest:

Multipronged approach distinguishes gene function changes that promote Parkinson’s disease from those that confer protection
What is infertility?
Growing Up Baylor: Dr. Andrea Bradford
Private equity, consolidation and the corporate transformation of medicine: opportunities and challenges for healthcare providers
From Match Day to residency: Guiding the next generation of physicians

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

ACTL6A

A new mechanism of cisplatin resistance in cancer, and how to reverse it

April 22, 2021 ACTL6A, cancer resistance to therapy, cisplatin, DNA repair, epigenetic chromatin remodeling, panobinostat, Research

ACLT6A overexpression confers cancer cells resistance to cisplatin, and researchers found a way to reverse it.

From the Labs: Image of the Month

From the Labs: Breast cancer cell clusters

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951